Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 09:49AM EDT. Market open.
| Previous close | 12.34 |
| Open | 12.40 |
| Bid | 12.20 x 400 |
| Ask | 12.43 x 100 |
| Day's range | 12.25 - 12.45 |
| 52-week range | 10.92 - 59.99 |
| Volume | |
| Avg. volume | 1,068,216 |
| Market cap | 741.442M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024 Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.63. Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
- Simply Wall St.
Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates
Investors in Sage Therapeutics, Inc. ( NASDAQ:SAGE ) had a good week, as its shares rose 2.7% to close at US$13.69...
- Zacks
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
© 2024 Yahoo. All rights reserved.